Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | STK17B | O94768 | 1/20 | 0.30 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21967075 | 0.99 | KMT2A (0.34) | MEN1KMT2AP2RX7LMNA | |
| SCHEMBL20913354 | 0.84 | P2RX7 (0.31) | KMT2AP2RX7 | |
| SCHEMBL20959581 | 0.84 | HTR3E (0.34) | KMT2AP2RX7 | |
| SCHEMBL2726118 | 0.83 | STK17B (0.48) | MEN1KMT2AP2RX7STK17BSTK17A | |
| SCHEMBL2724465 | 0.82 | STK17B (0.47) | MEN1KMT2AP2RX7STK17BSTK17A | |
| SCHEMBL25857102 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2AP2RX7LMNA | |
| SCHEMBL4578460 | 0.82 | LATS1 (0.40) | MEN1KMT2A | |
| SCHEMBL20959576 | 0.81 | PIN1 (0.46) | P2RX7LMNA | |
| SCHEMBL31669584 | 0.78 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL22977614 | 0.75 | MAPK1 (0.34) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927120-B2 | CDK inhibitors | GI Therapeutics, Inc. (NC) | 2021-02-23 | — | — | US | disclosed |
| US-20200277300-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | GI Therapeutics, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277300-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | MEN1 2275/4885KMT2A 276/4885P2RX7 4577/4885 |
| US-10927120-B2 | CDK inhibitors | CDK3, CDK9, CDK6 | MEN1 2275/4885KMT2A 276/4885P2RX7 4577/4885 |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | MEN1 3666/4885KMT2A 513/4885P2RX7 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.